Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sheffield
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Sheffield, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company13 Novartis Pharmaceuticals11 Janssen Research & Development, LLC10 AstraZeneca10 Novo Nordisk A/S9
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Sheffield

216 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
London, Leeds, Sheffield
2027-02-03
Not yet open
Novo Nordisk A/S
Phase 3
84
Birmingham, Cardiff, London, Oxford, Sheffield
2026-10-09
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
London, Sheffield
2026-08-31
Recruiting
AstraZeneca
Phase 3
1,072
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
2026-08-31
Recruiting
Trace Neuroscience, Inc.
Phase 1/2
30
Sheffield
2026-08-20
Recruiting
Hoffmann-La Roche
Phase 3
100
London, Sheffield
2026-08-18
Recruiting
GlaxoSmithKline
Phase 3
800
London, Sheffield
2026-07-27
Recruiting
Cochlear
Not applicable
20
London, Nottingham, Sheffield
2026-07-24
Recruiting
AstraZeneca
Phase 3
915
Bristol, Cambridge, Preston, Sheffield
2026-07-16
Recruiting
Axonics, Inc.
Observational
55
Sheffield
2026-07-02
Recruiting
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Not yet open
RAI Services Company
Not applicable
200
Cheshunt, Sheffield
2026-06
Recruiting
Pfizer
Phase 2
24
London, Bristol, Liverpool, Sheffield
2026-05-28
Recruiting
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
Recruiting
Lumos Pharma
Phase 3
150
Liverpool, London, Sheffield
2026-05-20
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Bath, London, Plymouth, Sheffield
2026-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
135
Manchester, Sheffield, Glasgow
2026-04-23
Recruiting
Hoffmann-La Roche
Phase 3
100
Birmingham, Cambridge, Sheffield
2026-04-15
Recruiting
Bristol-Myers Squibb
Phase 3
325
Exeter, London, Oxford, Chertsey, Sheffield, Crowborough, Motherwell
2026-03-25
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Cambridge, Glasgow, London, Sheffield, Swindon
2026-03-03
Recruiting
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
IDEAYA Biosciences
Phase 3
520
Metropolitan Borough of Wirral, London, Sheffield
2026-01-25
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Liverpool, London, Manchester, Sheffield
2026-01-22
Recruiting
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Belfast, Glasgow, Salford, Southampton
2026-01-07
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
Sheffield, Glasgow, London
2026-01-05
Recruiting
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
Recruiting
Vector Y Therapeutics
Phase 1/2
12
London, Sheffield
2025-12-19
Recruiting
argenx
Phase 2
60
Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds
2025-12-19
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Huddersfield, London, Manchester, Sheffield
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Cardiff, London, Manchester, Sheffield
2025-12-11
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Recruiting
GlaxoSmithKline
Phase 3
450
Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-12-02
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Recruiting
QED Therapeutics, a BridgeBio company
Phase 2
77
Glasgow, Manchester, Sheffield
2025-11-19
Active, closed
Bayer
Phase 2
60
Exeter, London, Sheffield, Sunderland
2025-11-19
Recruiting
Incyte Corporation
Phase 3
250
London, Sheffield, Walsall
2025-11-13
Recruiting
Pfizer
Phase 1
294
Sheffield
2025-11-06
Recruiting
Novo Nordisk A/S
Phase 1
30
Birmingham, London, Sheffield
2025-10-23
Recruiting
Alnylam Pharmaceuticals
Phase 1
50
Glasgow, London, Sheffield, Southampton
2025-10-15
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Glasgow, London, Sheffield
2025-09-30
Recruiting
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield
2025-09-29
Recruiting
Sanofi
Phase 4
218
Dundee, Newcastle upon Tyne, Southampton, Leicester, Bradford, Sheffield
2025-09-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Birmingham, Sheffield, Southampton
2025-08-21
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
London, Manchester, Oxford, Bath, Sheffield
2025-08-11
Recruiting
Autolus Limited
Phase 1
18
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Recruiting
AbbVie
Phase 3
120
Cambridge, Sheffield, Liverpool
2025-07-28
Recruiting
Pfizer
Phase 3
714
Truro, Sheffield, Southampton, Northwood, London, Taunton, Ipswich, Manchester
2025-07-23
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
426
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-07-16
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
Galderma R&D
Observational
1,000
London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds
2025-07-14
Active, closed
DBV Technologies
Phase 3
480
Glasgow, Leicester, London, Manchester, Sheffield, Southampton
2025-06-24
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Sheffield, Leeds, London, Swansea
2025-06-23
Recruiting
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Active, closed
Incyte Corporation
Phase 3
159
Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall
2025-06-17
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
London, Newcastle upon Tyne, Sheffield
2025-06-10
Active, closed
Biogen
Phase 3
255
London, Oxford, Sheffield
2025-06-09
Recruiting
Stoke Therapeutics, Inc
Phase 3
170
Glasgow, London, Sheffield
2025-06-04
Recruiting
Neurocrine Biosciences
Phase 3
200
London, Salford, Sheffield, Southampton
2025-05-30
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Belfast, Brighton, Cambridge, Cottingham, Coventry, London, Newcastle upon Tyne, Sheffield
2025-05-15
Recruiting
Biogen
Phase 3
454
London, Preston, Leicester, Sheffield, Stoke-on-Trent
2025-05-08
Active, closed
Cartesian Therapeutics
Phase 3
128
Birmingham, Sheffield
2025-05-06
By invitation
Vertex Pharmaceuticals Incorporated
Phase 2
44
Glasgow, London, Sheffield
2025-04-28
By invitation
QED Therapeutics, a BridgeBio company
Phase 2/3
24
Manchester, Sheffield, Glasgow
2025-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Sheffield, London
2025-04-22
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Great Yarmouth, Leicester, Liverpool, London, Sheffield
2025-04-21
Recruiting
Neurocrine Biosciences
Phase 3
850
Southampton, Sheffield, London, Manchester
2025-04-16
Recruiting
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Recruiting
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
NCT06846554Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd
Phase 2
48
London, Bath, Cambridge, Clydebank, Sheffield
2025-04-09
Recruiting
Daiichi Sankyo
Phase 3
582
Cambridge, London, Manchester, Oxford, Sheffield
2025-03-19
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield
2025-03-12
Recruiting
Pfizer
Phase 3
723
Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield
2025-03-11
Recruiting
Tyra Biosciences, Inc
Phase 2
92
London, Sheffield
2025-03-04
Active, closed
Definium Therapeutics US, Inc.
Phase 3
245
Glasgow, Gosforth, London, Manchester, Sheffield
2025-01-29
Recruiting
Biogen
Phase 1
78
Sheffield
2025-01-16
Active, closed
argenx
Phase 3
631
Southampton, Sheffield, Cannock
2025-01-15
Recruiting
Novo Nordisk A/S
Phase 3
480
London, Manchester, Sheffield
2025-01-10
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Birmingham, London, Newcastle upon Tyne, Sheffield
2024-12-19
Active, closed
argenx
Phase 3
154
Glasgow, Oxford, Salford, Sheffield, Taunton
2024-12-18
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sheffield, London
2024-12-17
Recruiting
UCB Biopharma SRL
Phase 3
450
Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
2024-11-21
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Sheffield, Stoke-on-Trent
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Sheffield
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Sheffield, Cambridge, London
2024-10-24
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
300
Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield
2024-10-18
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Sheffield, Farnborough, London, Stoke-on-Trent
2024-10-17
Active, closed
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Sheffield, London
2024-09-04
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Cambridge, Clydebank, London, Newcastle, Sheffield
2024-09-03
Recruiting
Alimera Sciences
Phase 4
25
Bristol, Sheffield
2024-08-31
Active, closed
Sanofi
Phase 2
229
Oxford, Sheffield
2024-08-29
Recruiting
Eli Lilly and Company
Phase 1
48
London, Sheffield, Southampton
2024-08-15
Recruiting
AbbVie
Phase 3
110
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Active, closed
Avidity Biosciences, Inc.
Phase 2
84
London, Sheffield
2024-07-25
Recruiting
Amgen
Phase 3
450
Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton
2024-07-17
Recruiting
Hydra Registry - UK
NCT06507579Aortic Valve Stenosis
Sahajanand Medical Technologies Limited
Observational
250
Sheffield, Belfast, Cambridge, Cottingham
2024-07-11
Recruiting
AbbVie
Phase 3
40
Sheffield, Bristol, Liverpool
2024-07-08
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
London, Nottingham, Sheffield
2024-06-25
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Barnet, Bristol, Exeter, Halifax, High Wycombe, London, Oldham, Sheffield
2024-06-17
Recruiting
LEO Pharma
Phase 3
195
Lincoln, London, Sheffield, Southampton
2024-06-10
Recruiting
QED Therapeutics, a BridgeBio company
Observational
150
London, Manchester, Sheffield, Glasgow
2024-06-05
Recruiting
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Exeter, Bournemouth, Bristol, Edinburgh, London, Sheffield, Swansea
2024-05-20
Active, closed
Encoded Therapeutics
Phase 1/2
5
Glasgow, London, Sheffield
2024-05-09
Active, closed
Amgen
Phase 3
111
Glasgow, Manchester, Sheffield
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
43
Birmingham, Manchester, Sheffield
2024-04-02
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Glasgow, London, Manchester, Oxford, Sheffield
2024-03-13
Recruiting
Eli Lilly and Company
Phase 3
90
Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel
2024-03-13
Active, closed
Acumen Pharmaceuticals
Phase 2
542
London, Winchester, Motherwell, Preston, Guildford, Sheffield, Bristol
2024-02-29
Active, closed
Sanofi
Phase 4
48
Sheffield
2024-02-22
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
Glasgow, London, Salford, Sheffield
2024-02-20
Recruiting
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Recruiting
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Active, closed
Aura Biosciences
Phase 3
108
London, Sheffield
2023-12-06
Active, closed
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Alcyone Therapeutics, Inc
Not applicable
90
Sheffield
2023-11-27
Active, closed
AstraZeneca
Phase 3
314
Cannock, Leeds, London, Sheffield
2023-11-08
Active, closed
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
Leicester, London, Sheffield
2023-10-26
Recruiting
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Bristol, Clydebank, Dorchester, Exeter, High Wycombe, Lincoln, London, Sheffield
2023-04-11
Active, closed
Sanofi
Phase 2
999
London, Edinburgh, Sheffield
2023-04-03
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Edinburgh, London, Plymouth, Scunthorpe, Sheffield, Stevenage, Truro
2023-03-23
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
London, Sheffield
2023-03-16
Active, closed
DBV Technologies
Phase 3
600
London, Manchester, Sheffield, Southampton
2023-02-21
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Belfast, Cardiff, London, Sheffield
2023-02-13
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Sheffield, London, Middlesbrough, Wolverhampton, Cambridge
2023-01-25
Recruiting
Eli Lilly and Company
Phase 1
677
Manchester, Sheffield
2023-01-12
Active, closed
Exelixis
Phase 3
317
Sheffield, London
2023-01-01
Active, closed
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459Amyotrophic Lateral Sclerosis
QurAlis Corporation
Phase 1
69
Sheffield, London
2022-12-16
Recruiting
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Liverpool, London, Oxford, Sheffield
2022-11-21
Active, closed
Biogen
Phase 1
62
Bloomsbury, Sheffield
2022-10-10
Recruiting
Ellipses Pharma
Phase 1/2
265
London, Manchester, Sheffield
2022-09-30
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Birmingham, Devon, Glasgow, London, Sheffield
2022-09-23
Active, closed
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Active, closed
HEAL-IST IDE Trial
NCT05280093Inappropriate Sinus Tachycardia
AtriCure, Inc.
Not applicable
142
Sheffield
2022-05-31
By invitation
AstraZeneca
Phase 3
214
London, Sheffield
2022-04-19
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
Cambridge, Glasgow, London, Manchester, Sheffield
2022-04-14
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Bristol, London, Manchester, Sheffield
2022-03-08
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Manchester, Sheffield
2022-02-21
Recruiting
Alnylam Pharmaceuticals
Phase 1
60
Huntley Street, Sheffield
2022-02-04
Active, closed
Immunic AG
Phase 3
1,100
Sheffield
2022-01-12
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Sheffield, Birmingham
2021-12-14
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
300
Birmingham, Bristol, Glasgow, London, Manchester, Sheffield
2021-12-06
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Bristol, Edinburgh, Leeds, London, Peterborough, Sheffield
2021-12-02
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Birmingham, Cambridge, London, Sheffield, Southampton
2021-10-18
Recruiting
Safe and Timely Antithrombotic Removal (STAR) Registry
NCT05077124Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
CytoSorbents, Inc
Observational
1,000
Blackpool, London, Sheffield
2021-09-30
Active, closed
Inventiva Pharma
Phase 3
1,000
London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bradford, Cambridge, London, Londonderry, North Shields, Portadown, Sheffield, Stevenage
2021-08-14
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield
2021-07-16
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
Active, closed
Biogen
Phase 3
158
Sheffield
2021-05-17
Active, closed
Pfizer
Phase 3
599
Exeter, Maidstone, Preston, Edinburgh, Glasgow, Sheffield, Birmingham, London
2021-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield
2021-05-12
Active, closed
Hoffmann-La Roche
Phase 3
761
Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton
2021-05-03
Active, closed
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Sheffield, London
2021-03-15
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Active, closed
Provention Bio, a Sanofi Company
Observational
188
Sheffield
2020-10-26
Active, closed
BioMarin Pharmaceutical
Phase 2
20
London, Sheffield
2020-10-10
Active, closed
argenx
Phase 2
229
London, Oxford, Sheffield
2020-09-18
Recruiting
Epygenix
Phase 3
150
Cardiff, London, Sheffield
2020-09-15
Active, closed
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Active, closed
Actelion
Phase 3
935
London, Newcastle upon Tyne, Sheffield
2020-06-30
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Glasgow, London, Oxford, Plymouth, Preston, Sheffield, Southampton
2020-03-30
Recruiting
Acurable Ltd.
Observational
200
Sheffield, Southampton
2020-02-19
Active, closed
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Cardiff, Sheffield, Glasgow, London
2020-02-11
Active, closed
Advanced Accelerator Applications
Phase 3
226
Bristol, London, Sheffield
2020-01-08
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Belfast, London, Sheffield
2019-11-13
Active, closed
Novo Nordisk A/S
Phase 3
134
Birmingham, London, Manchester, Nottingham, Sheffield
2019-10-21
Active, closed
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Active, closed
Novartis Pharmaceuticals
Phase 3
254
Sheffield, Cambridge, London
2019-07-26
Active, closed
AstraZeneca
Phase 3
923
Edinburgh, London, Sheffield, Surrey, York
2019-06-25
Active, closed
BioMarin Pharmaceutical
Phase 2
73
London, Sheffield
2019-06-12
Active, closed
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Recruiting
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
By invitation
Novo Nordisk A/S
Observational
60
Aberdeen, Cardiff, Manchester, Sheffield
2019-04-01
Active, closed
Eisai Inc.
Phase 3
1,906
Plymouth, Southampton, Sheffield, Birmingham, Guildford, London
2019-03-27
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
453
Glasgow, Leeds, London, Sheffield
2019-02-08
Recruiting
RECORDATI GROUP
Observational
95
London, Sheffield
2019-01-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Cambridge, Cottingham-Hull, London, Sheffield
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Oxford, Manchester, Newcastle upon Tyne, Sheffield
2018-12-12
Active, closed
Advanced Accelerator Applications
Observational
1,014
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield
2018-11-28
Active, closed
AstraZeneca
Phase 3
1,063
Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Guildford, Manchester, Sheffield, Southampton, Swansea
2018-10-31
By invitation
Novo Nordisk A/S
Observational
10
Sheffield
2018-10-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston
2018-08-21
Active, closed
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
BioMarin Pharmaceutical
Phase 3
119
London, Sheffield
2017-12-12
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield
2017-08-23
Active, closed
Medtronic
Observational
1,092
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2017-08-21
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Sheffield, Glasgow, London, Gloucester, Oxford
2017-06-26
Active, closed
Tesaro, Inc.
Phase 3
733
Blackburn, Edinburgh, Exeter, Glasgow, London, Portsmouth, Sheffield, Truro
2016-07-11
Active, closed
UK Infinity, Post-Market Clinical Follow-up Study
NCT03063593Arthritis, Rheumatoid, Post-traumatic Osteoarthritis, Degenerative Arthritis
Stryker Trauma and Extremities
Observational
500
Torquay, Bournemouth, Bothwell, Oswestry, Sheffield, Nottingham, Bristol, Edinburgh
2016-04-29
Active, closed
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Active, closed
Regeneron Pharmaceuticals
Phase 3
880
London, Manchester, Sheffield
2015-10-15
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Rows per page Showing 1–216 of 216
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/sheffield

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 216 of those studies with a site in Sheffield.

How many clinical trials are recruiting in Sheffield?

107 of the 216 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 4 have not yet opened recruitment, 96 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sheffield), 216 studies
PhaseStudiesRecruitingShare
Phase 31276558.8%
Phase 2311014.4%
Observational2089.3%
Phase 11185.1%
Phase 1/2964.2%
Not applicable733.2%
Phase 2/3753.2%
Phase 4421.9%

Most active sponsors

Lead sponsors with the most studies (Sheffield)
Lead sponsorStudiesRecruiting
Eli Lilly and Company1310
Novartis Pharmaceuticals112
AstraZeneca102
Janssen Research & Development, LLC105
Novo Nordisk A/S92
Biogen73
Merck Sharp & Dohme LLC72
AbbVie64
argenx51
Bristol-Myers Squibb55
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.